Ketamine has been shown to produce rapid and robust antidepressant effects in depressed individuals; however, its abuse potential and adverse psychotomimetic effects limit its widespread use. Dextromethorphan (DM) may serve as a safer alternative on the basis of pharmacodynamic similarities to ketamine. In this proof-of-concept study, behavioral and biochemical analyses were carried out to evaluate the potential involvement of brain-derived neurotrophic factor (BDNF) in the antidepressant-like effects of DM in mice, with comparisons to ketamine and imipramine. Male Swiss, Webster mice were injected with DM, ketamine, or imipramine and their behaviors were evaluated in the forced-swim test and the open-field test. Western blots were used to measure BDNF and its precursor, pro-BDNF, protein expression in the hippocampus and the frontal cortex of these mice. Our results show that both DM and imipramine reduced immobility time in the forced-swim test without affecting locomotor activity, whereas ketamine reduced immobility time and increased locomotor activity. Ketamine also rapidly (within 40 min) increased pro-BDNF expression in an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-dependent manner in the hippocampus, whereas DM and imipramine did not alter pro-BDNF or BDNF levels in either the hippocampus or the frontal cortex within this timeframe. These data show that DM shares some features with both ketamine and imipramine. Additional studies examining DM may aid in the development of more rapid, safe, and efficacious antidepressant treatments.
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Introduction
Most pharmaceutical agents available for the treatment of depression have similar mechanisms of action targeting monoaminergic systems, remain ineffective in a third of patients, and have a delayed clinical efficacy of several weeks to months [1] . Notably, accumulating evidence indicates that subanesthetic doses of the glutamate N-methyl-D-aspartate antagonist ketamine can produce robust and rapid antidepressant effects even in treatmentresistant individuals [2] . However, the widespread use of ketamine is limited by abuse liability and adverse effects [3] .
In the search for alternatives to ketamine, dextromethorphan (DM) was postulated to have fast-acting antidepressant activity on the basis of pharmacodynamic similarities to ketamine [4] . In contrast to ketamine, DM has been available over the counter for over 50 years as an antitussive, with a wide margin of safety, and may thus serve as a safer alternative to be utilized for depressed patients. Recently, DM has also been approved for use in the treatment of pseudobulbar affect in combination with a low dose of the cytochrome P450 2D6 inhibitor quinidine (to slow down the first-pass metabolism of DM) in the USA and Europe. Importantly, in a retrospective study involving patients with treatment-resistant bipolar depression, some patients reported improvements in mood within 1-2 days of initiating treatment with DM/ quinidine or having the dose increased to twice a day [5] .
In preclinical studies, we found that DM exerts antidepressant-like effects in mice using the forced-swim test (FST) and the tail-suspension test, two well-established and commonly used animal models for predicting antidepressant efficacy [6, 7] . Moreover, treatment with the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonist NBQX (2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f] quinoxaline-7-sulfonamide disodium salt) attenuated the antidepressant-like effects of DM in these behavioral tests [6, 7] . Earlier studies suggest that AMPA receptors are associated with producing a faster onset of antidepressant efficacy [8, 9] and are critical to the fast-acting antidepressant effects of ketamine [10] [11] [12] [13] . They may therefore contribute toward the faster onset of antidepressant actions produced by DM [5] .
A growing body of evidence suggests that neural plasticity may be a final common pathway of different antidepressant therapies and may explain the delay in efficacy with conventional antidepressants [9] . An important contributor driving neural adaptation and antidepressant-like effects is brain-derived neurotrophic factor (BDNF) [14] . BDNF protects neurons from injury, at least in part, by inhibiting apoptosis and by stimulating neurite sprouting and neuronal reorganization [15] . BDNF is formed from its precursor, pro-BDNF. Changes in pro-BDNF and mature BDNF have been shown in both preclinical and clinical studies [14, 16] . For instance, postmortem studies have reported reductions in BDNF levels in the prefrontal cortex and the hippocampus of suicide victims who were depressed relative to matched controls or patients taking an antidepressant at the time of death [17] . In contrast, antidepressant treatment has led to upregulation of BDNF in the hippocampus of patients with major depression at the time of death compared with untreated patients [18] , and an intracerebral infusion of BDNF results in an antidepressant-like effect in animal models of depression [19] . Interestingly, chronic, but not acute, treatment with classic antidepressant drugs increases BDNF expression [14] , whereas acute and/or chronic treatment with ketamine can promote increases in BDNF and pro-BDNF expression [13, [20] [21] [22] [23] [24] . Thus, pharmaceutical agents capable of quickly enhancing BDNF, and possibly pro-BDNF, levels may aid in the development of novel, effective, and fast-acting antidepressant drugs.
In the present study, the behavioral effects of DM were examined by additional neurobiochemical analyses. Specifically, the effects of DM on immobility time in the FST, the most predictive rodent model for screening potential antidepressant drugs [25] , and locomotor activity in the open-field test (OFT) were studied in mice. Fastacting and conventional antidepressants represented by ketamine and imipramine, respectively, were used as reference drugs in these studies. In addition, we evaluated the effects of these compounds on pro-BDNF and BDNF protein expression in the hippocampus and the frontal cortex, two key areas involved in depression [26] . Because the precursor and mature forms of BDNF may be regulated independently and have been separately shown to rapidly increase following the administration of ketamine [13, [20] [21] [22] [23] [24] , we evaluated them individually rather than as a ratio or in combination. Also, because the antidepressant-like behaviors of DM have only been established recently and at a single time point [6, 7] , we used this known antidepressant effective time point to evaluate potential biochemical changes. Finally, as AMPA receptors have been previously shown to be critical for the antidepressant-like effects of DM and ketamine [7] , we also examined their role in modulating the potential behavioral and biochemical effects discussed here.
Materials and methods

Animals
Male, Swiss Webster mice (24-28 g; Harlan, Frederick, Maryland, USA) were housed with food and water ad libitum, with a 12:12 h light-dark cycle. Animals were housed in groups of five for at least 1 week before the initiation of experiments. All procedures were performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The Institutional Animal Care and Use Committee at West Virginia University (Morgantown, West Virginia, USA) approved the protocol and all efforts were made to minimize suffering.
Drugs and chemicals
DM hydrobromide, ketamine hydrochloride, and imipramine hydrochloride were purchased from Sigma-Aldrich (St Louis, Missouri, USA). NBQX was obtained from Tocris (Ellisville, Missouri, USA). All compounds were dissolved in sterile saline (Teknova, Hollister, California, USA).
Experimental groups
Mice received intraperitoneal injections of saline or drug solutions (imipramine, ketamine, or DM) at a volume of 10 ml/kg of body weight after acclimatization to the OFT 30 min before the FST. Pretreatment with NQBX was administered 15 min before ketamine. Otherwise, pretreatment with saline was administered before a second drug (imipramine, ketamine, or DM). The behavioral experiments were conducted between 10:00 a.m. and 2:00 p.m. Immediately after the behavioral tests (N = 10/ group, for a total of 50 mice), the animals were killed by decapitation and the hippocampus and the frontal cortex were extracted for Western blot analysis (N = 8-10/ group).
Open-field test
Locomotor activity was measured in the OFT utilizing the Photobeam Activity System-Open Field (San Diego Instruments, San Diego, California, USA), an automated activity-monitoring system. Before locomotor activity measurements, animals were acclimated to the testing facility for at least 30 min and habituated to the testing chambers for an additional 30 min. Each testing chamber consisted of a Plexiglas housing (San Diego Instruments, San Diego, California, USA) and a 16 × 16 photobeam array to detect lateral (ambulatory and fine) movements, with a separate 16 photobeam array to detect rearing activity. Subsequent to the acclimation period, animals were treated and placed back in their respective chambers. Ambulatory, fine, and rearing movements were quantified and summated as a measure of the total locomotor activity for the next 30 min.
Forced-swim test
Immediately after the locomotor measurements, mice were subjected to the FST, which was adapted with some modifications from the behavioral despair test described by Castagné et al. [27] . Mice were placed in individual cylinders of water (10 cm deep, 12.7 cm diameter) for a total of 6 min. The initial 2 min was an acclimation period and not scored. During the remaining 4 min, immobility time was quantified using AnyMaze, version 4.63 video tracking software (Stoelting Co., Wood Dale, Illinois, USA). Immobility was defined as no activity other than that required for maintaining the animal's head above the surface of the water. AnyMaze software settings were as follows: acclimatization period = 120 s, test duration = 240 s, minimum immobility time = 2000 ms (2 s), and immobility sensitivity = 65%.
Western blot
Immediately after completion of the behavioral measurements in the FST, animals were killed by decapitation. The brains were then removed and bilateral hippocampus and frontal cortex samples dissected, flash frozen, and stored at − 80°C. To dissect the frontal cortex, we first cut off the olfactory bulb. We then divided the cortex into two hemispheres and sectioned off the tissue in front of the white matter (corpus callosum). Tissues were homogenized and lysed in RIPA (radioimmunoprecipitation assay) buffer (Teknova, Hollister, California, USA) containing protease inhibitors (cOmplete ULTRA Protease Inhibitor Cocktail Tablets; Roche, Indianapolis, Indiana, USA) and phosphatase inhibitors (phosSTOP Phosphatase Inhibitor Cocktail Tablets; Roche), and centrifuged at 13 000g for 30 min at 4°C. The supernatants were assayed for total protein concentrations using BCA (bicinchoninic acid assay) protein assay kits (Pierce, Rockford, Illinois). Samples were run at 20 or 30 µg of protein/well using Bolt Bis-Tris Plus 10% precast 15 well gels (Life Technologies, Grand Island, New York, USA) in combination with 2 × Laemmli sample buffer (Bio-Rad, Hercules, California, USA). After electrophoresis and transfer onto polyvinylidene fluoride membranes, blots were incubated with Odyssey blocking buffer (LI-COR Biosciences, Lincoln, Nebraska, USA) for 1 h at room temperature and then with the appropriate primary antibodies overnight at 4°C (rabbit anti-pro-BDNF catalog no. ANT006, 1 : 600, Alomone Labs, Jerusalem, Israel; rabbit anti-BDNF catalog no. ANT010, 1 : 200, Alomone Labs; or mouse antiα-tubulin catalog no. ab7291, 1 : 100 000, (Abcam, Cambridge, Massachusetts, USA). After washing with Tris-buffered saline containing 0.1% Tween 20, the blots were incubated with the secondary antibodies (IRDye 800CW goat anti-mouse or 700CW goat anti-rabbit, 1 : 10 000; LI-COR Biosciences) containing 0.01% SDS for 45 min at room temperature. Visualization was carried out using an Odyssey Classic Infrared Imaging System (LI-COR Biosciences). Detected bands were quantified using Image Studio Lite Software (LI-COR Biosciences), normalized to relevant α-tubulin values, and expressed as a percent of control density within individual blots.
Data analysis
Data from all experiments were analyzed using GraphPad Prism 5.0 (GraphPad Software. Inc., San Diego, California, USA) by a Student's unpaired t-test or by oneway analysis of variance (ANOVA) followed by Tukey's multiple comparisons tests. Data are represented as mean SEM. P value less than 0.05 was considered statistically significant for all data analyzed.
Results
Using previously established antidepressant effective doses of the compounds of interest [6, 7] , we confirmed that the fast-acting antidepressant drug ketamine and conventional antidepressant imipramine both reduced immobility time in the FST ( Fig. 1a and b ; t = 4.31, P < 0.001; and t = 6.22, P < 0.0001, respectively). Similar to the reference drugs, DM significantly reduced immobility time ( Fig. 1c ; t = 5.00, P < 0.0001).
In the OFT, ketamine produced significant increases in locomotor activity ( Fig. 1d ; t = 4.14, P < 0.001). Imipramine and DM, however, did not significantly alter locomotor activity [ Fig. 1e and f; t = 0.48 and t = 0.67, nonsignificant (NS), respectively].
As shown in Fig. 2a and b , ketamine significantly increased pro-BDNF (∼32-34 kDa) levels in the hippocampus (t = 2.53, P < 0.05), but not the frontal cortex (1.64, NS) 40 min after injection. Imipramine did not alter pro-BDNF protein expression in the hippocampus (t = 0.26, NS) or the frontal cortex (t = 1.37, NS) at 40 min after injection. Similar to imipramine, DM also did not increase pro-BDNF levels in the hippocampus (t = 0.71, NS) or the frontal cortex (t = 0.83, NS) 40 min after injection.
With respect to the mature form of BDNF (∼18 kDa), no alterations in BDNF protein expression were observed in the hippocampus (Fig. 3a) or the frontal cortex ( Fig. 3b) for any of the drugs tested (ketamine: t = 0.13 or 0.03; imipramine: t = 0.78 or 0.95; DM: t = 1.55 or 0.37, respectively).
Similar to earlier reports that AMPA receptors mediate many of the antidepressant-relevant behavioral and biochemical effects of ketamine [10, 11, 21] , here, we observed that pretreatment with an AMPA receptor antagonist (NBQX) attenuated the antidepressant-like effects of ketamine in the FST (Fig. 4a) , stimulatory effects in the OFT (Fig. 4b) , and increases in pro-BDNF protein expression in the hippocampus (Fig. 4c ). For the FST antagonism study, the overall ANOVA was significant [F(2,27) = 6.85; P < 0.01]. Post-hoc Tukey's multiple comparisons tests confirmed that the ketamine treatment group differed significantly from saline (q = 5.20, P < 0.01) and the NBQX + ketamine group did not differ significantly from saline (q = 2.09, NS). However, the difference in the antidepressant-like effects of ketamine in the absence and presence of NBQX was Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved. , and increase in hippocampal pro-BDNF levels (c). Representative images of the protein are shown on the left and the cumulative graphed data are shown on the right (c). In the behavioral data, 10 mice were used for each group. In the biochemical data, 10 mice were used for the saline group and 8 were used for the ketamine and NBQX + ketamine groups. Data shown are expressed as mean SEM. *P < 0.05, **P < 0.01, ***P < 0.001, versus the saline-treated group; # P < 0.05, ### P < 0.001, versus the ketamine-treated group; Tukey's post-hoc tests. AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; BDNF, brain-derived neurotrophic factor; KET, ketamine; Sal, saline. not significant (q = 3.11, NS), suggesting partial attenuation of the effects. In the OFT, the overall ANOVA was significant [F(2,27) = 17.73; P < 0.0001]. Post-hoc Tukey's test confirmed the ability of NBQX to significantly block the stimulatory effects of ketamine (q = 7.55, P < 0.001). For hippocampal pro-BDNF levels, the overall ANOVA was also significant [F(2,23) = 4.78, P < 0.05]. Post-hoc Tukey's multiple-comparison tests showed that the ketamine treatment group differed significantly from saline (q = 3.96, P < 0.05) as well as the NBQX + ketamine group (q = 3.68, P < 0.05). Although not shown, the NBQX treatment group showed no significant effects in the FST (t = 0.19, NS), OFT (t = 1.02, NS), or on hippocampal pro-BDNF protein expression (t = 1.86, NS) compared with the saline control group.
Discussion
This pilot study indicates that DM may be effective for treating depression and warrants further investigation as a novel fast-acting treatment. In our model, DM reduced immobility time in the FST in mice with an efficacy comparable to that of the fast-acting antidepressant ketamine and conventional tricyclic antidepressant imipramine. This is consistent with previous findings from our lab, which showed dose-dependent decreases in immobility time in mice following the administration of DM, ketamine, and imipramine [6, 7, 28] .
Previous locomotor findings for ketamine and DM have varied, with some studies showing no effects and others showing increases in spontaneous locomotor activity [6, 7, 28, 29] . Here, we showed that DM did not significantly affect spontaneous locomotor activity in the OFT. In contrast, ketamine elicited a significant increase in locomotor activity that is suggestive of stimulatory effects. Under the same testing conditions, a slightly higher dose of ketamine (40 mg/kg, intraperitoneally) than that used here had shown antidepressant-like effects in the FST without affecting locomotor activity [28] . The concurrence of stimulatory effects with antidepressantlike actions for ketamine in this study suggests that the two effects could be related, although not necessarily dependent on one another. Notably, the fact that ketamine, but not DM, had significant stimulatory effects in this study further suggests that DM can elicit antidepressant-like efficacy with less abuse liability and reduced side effects compared with ketamine.
Alterations in pro-BDNF and mature BDNF levels have been found in animal models of depression and in depressed human populations [14, 16] . Extending the findings from previous studies, which suggested pro-BDNF associations with ketamine antidepressant efficacy [21, 24] , we found that a single administration of ketamine produced a rapid increase in pro-BDNF. We observed the increase in the mouse hippocampus pro-BDNF levels within 40 min after injection, which is a time frame similar to the detection of antidepressant effects reported for intravenous or intranasal ketamine administration in some depressed human patients [30, 31] . With respect to conventional antidepressants, Musazzi et al. [32] found that the conventional antidepressants fluoxetine and reboxetine upregulated pro-BDNF protein expression in the hippocampus of male Sprague-Dawley rats around week 2-3 of treatment, but not at week 1. Unsurprisingly, we did not find a significant change in pro-BDNF expression within 40 min of imipramine administration. The concurrence of the decrease in immobility time and the increase in pro-BDNF after ketamine, but not imipramine, treatment may in part explain ketamine's rapid, compared with imipramine's delayed, onset of antidepressant efficacy. It is important to keep in mind that although ketamine has been shown to increase pro-BDNF expressions without a concomitant increase in locomotor activity in the previous two studies [21, 24] , we cannot rule out a possible pro-BDNF association with mobility. Although evidence for this association is lacking at present, Macias et al. [33] had shown that locomotor exercise can alter the expression of pro-BDNF (and BDNF) in the spinal cord of adult rats.
For mature BDNF, many studies have implicated its crucial role in depression [14] and have examined the effects of ketamine on BDNF levels [13, [20] [21] [22] [23] . Indeed, acute administration of ketamine has been shown to increase BDNF levels in rodents in key brain regions involved in depression, including the hippocampus and the prefrontal cortex [13, [20] [21] [22] [23] . Following a single ketamine administration, increases in BDNF levels have occurred as early as 30 min after injection in the mouse [21] and rat [23] hippocampus. We, however, observed no changes in BDNF levels at 40 min after injection, which, compared with the earlier mouse study, may be because of differences in mouse strains (Swiss Webster vs. C57BL/6), the ketamine doses used (30 vs. 3 mg/kg, intraperitoneally), and experimental laboratory conditions. Importantly, however, some other studies have also reported dissociations between antidepressant-like effects and mature BDNF protein changes following the administration of ketamine [12, 20] . The possibility that other (non-BDNF) signaling pathways also mediate ketamine-induced antidepressant effects is supported by studies in BDNF knockout mice. In particular, treatment with ketamine (50 mg/kg, intraperitoneally) retained antidepressant-like effects in the FST in heterozygous BDNF knockout (bdnf + / − ) C57BL/6 mice and failed to alter BDNF levels in the hippocampus when assessed at 45 min or 7 days after drug administration [12] . These results suggest that ketamine can produce antidepressant-like effects independent of the mature BDNF signaling pathway. Moreover, the effects of ketamine on hippocampal BDNF appear to be time dependent. Autry et al. [21] found an increase in mouse hippocampal BDNF expression within 30 min of administration, but not at 24 h. Fraga et al. [34] in contrast, found a decrease in BDNF levels in rat hippocampus at 1 and 6 h The incongruity between an increase in pro-BDNF levels and no corresponding change in BDNF levels in our study remains unclear. This is different from the findings obtained by Autry et al. [21] which showed that ketamine increased hippocampal pro-BDNF as well as BDNF within 30 min of administration. It was initially believed that only secreted mature BDNF was biologically active, and that pro-BDNF, which localizes within the cell, served as an inactive precursor. However, emerging evidence indicates that pro-BDNF and mature BDNF elicit different and seemingly opposing biological effects through the p75 neurotrophin receptor and tropomyosin receptor kinase B, respectively [14, 35] . Activation of p75 neurotrophin receptor by pro-BDNF has been shown to induce neuronal atrophy and apoptosis, whereas activation of the tropomyosin receptor kinase B has been associated with growth and survival, suggesting a 'yin and yang' model of neurotrophin action [35] . Which of these activities predominate at given times is not yet clear, and whether the increase in pro-BDNF levels following acute ketamine administration in this study is detrimental at the cellular level requires further investigation. It may be that the dynamic changes in pro-BDNF and BDNF levels are important for the optimal tuning of neuronal plasticity, whereby structural increases are balanced by programmed neuronal death, neurite retraction, and synaptic pruning [14] .
Finally, here we also report that the increase in pro-BDNF levels in the hippocampus and antidepressant-like effects of ketamine are mediated in part through AMPA receptors. In a study by Reus et al. [24] , ketamine increased pro-BDNF protein expression in the rat hippocampus and the nucleus accumbens, with a mitogen-activated protein kinase kinase inhibitor blocking the effects of ketamine in the nucleus accumbens. They also reported that the mitogen-activated protein kinase kinase inhibitor attenuated the antidepressant-like effects of ketamine in the FST. Our findings thus provide an additional, or upstream, mechanism by which ketamine may promote pro-BDNF levels in specific brain regions. These findings are consistent with previous reports implicating the critical role of AMPA receptors in mediating the antidepressant-like effects of ketamine [10, 11, 21] . In addition, although the antidepressant-like effects of DM also appear to be AMPA receptor mediated [7] , its lack of effects on pro-BDNF suggests that additional mechanisms are at play downstream of AMPA receptor activation.
Importantly, our data did not evaluate the effects of ketamine or DM on pro-BDNF or BNDF levels at other time points. In a double-blind study, treatment with DM (60 mg/day) plus valproic acid produced a small increase in plasma BDNF levels from baseline at 12 weeks, and the increase was significantly higher than the placebo plus valproic acid group [36] . In addition, in a retrospective study, daily administration of DM/quinidine has been shown to produce antidepressant effects in patients with bipolar depression within 1-2 days of treatment [5] , rather than hours as observed with ketamine [2, 30, 37] . Further studies to determine whether DM can promote increases in BDNF or pro-BDNF at later time points or after subchronic dosing are worthy of future investigation.
Overall, our results suggest that DM may produce antidepressant actions, while reducing problematic stimulatory effects observed with ketamine. Moreover, in contrast to the AMPA-dependent increase in hippocampal pro-BDNF levels of ketamine, DM does not appear to rapidly alter pro-BDNF levels, while still producing antidepressant-like effects. Along with earlier studies, these findings indicate that DM shares some, but not all, antidepressant-related mechanisms with ketamine. Additional studies should be carried out to identify specific molecular mechanisms through which DM exerts its antidepressant effects. Furthermore, once these preclinical studies have been validated, it will be necessary to determine the efficacy of DM for treating depression in patients.
